There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Emergent Biosolutions (EBS – Research Report) and Vera Therapeutics (VERA – Research Report) with bullish sentiments.
Emergent Biosolutions (EBS)
In a report released today, Robert Wasserman from Benchmark Co. maintained a Buy rating on Emergent Biosolutions, with a price target of $5.00. The company’s shares closed last Wednesday at $2.23, close to its 52-week low of $1.42.
According to TipRanks.com, Wasserman is a 1-star analyst with an average return of
Emergent Biosolutions has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
See Insiders’ Hot Stocks on TipRanks >>
Vera Therapeutics (VERA)
In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Vera Therapeutics, with a price target of $56.00. The company’s shares closed last Wednesday at $41.62.
According to TipRanks.com, Katkhuda is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vera Therapeutics with a $45.78 average price target, implying a 25.3% upside from current levels. In a report issued on March 27, Guggenheim also maintained a Buy rating on the stock with a $56.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EBS:
- Emergent BioSolutions continues to broaden access of NARCAN nasal spray
- Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
- Emergent BioSolutions receives NAI status for Baltimore Bayview facility
- Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
- Emergent BioSolutions upgraded to Buy at Benchmark after ‘upbeat’ Q4 report
